Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Andrew M Evens; Joseph M Connors; Anas Younes; Stephen M Ansell; Won Seog Kim; John Radford; Tatyana Feldman; Joseph Tuscano; Kerry J Savage; Yasuhiro Oki; Andrew Grigg; Christopher Pocock; Monika Dlugosz-Danecka; Keenan Fenton; Andres Forero-Torres; Rachael Liu; Hina Jolin; Ashish Gautam; Andrea Gallamini

doi:10.3324/haematol.2021.278438

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Andrew M Evens, Joseph M Connors, Anas Younes, Stephen M Ansell, Won Seog Kim, John Radford, Tatyana Feldman, Joseph Tuscano, Kerry J Savage, Yasuhiro Oki, Andrew Grigg, Christopher Pocock, Monika Dlugosz-Danecka, Keenan Fenton, Andres Forero-Torres, Rachael Liu, Hina Jolin, Ashish Gautam, Andrea Gallamini

Research output: Contribution to journal › Article › peer-review

Abstract

Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.

Original language	English
Journal	Haematologica
Early online date	24 Jun 2021
DOIs	https://doi.org/10.3324/haematol.2021.278438
Publication status	Published - 24 Jun 2021

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3324/haematol.2021.278438

Cite this

Evens, A. M., Connors, J. M., Younes, A., Ansell, S. M., Kim, W. S., Radford, J., Feldman, T., Tuscano, J., Savage, K. J., Oki, Y., Grigg, A., Pocock, C., Dlugosz-Danecka, M., Fenton, K., Forero-Torres, A., Liu, R., Jolin, H., Gautam, A., & Gallamini, A. (2021). Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. https://doi.org/10.3324/haematol.2021.278438

@article{e1456b23a0ce4f4c881b1b26d25a7670,

title = "Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study",

abstract = "Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.",

author = "Evens, {Andrew M} and Connors, {Joseph M} and Anas Younes and Ansell, {Stephen M} and Kim, {Won Seog} and John Radford and Tatyana Feldman and Joseph Tuscano and Savage, {Kerry J} and Yasuhiro Oki and Andrew Grigg and Christopher Pocock and Monika Dlugosz-Danecka and Keenan Fenton and Andres Forero-Torres and Rachael Liu and Hina Jolin and Ashish Gautam and Andrea Gallamini",

year = "2021",

month = jun,

day = "24",

doi = "10.3324/haematol.2021.278438",

language = "English",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Evens, AM, Connors, JM, Younes, A, Ansell, SM, Kim, WS, Radford, J, Feldman, T, Tuscano, J, Savage, KJ, Oki, Y, Grigg, A, Pocock, C, Dlugosz-Danecka, M, Fenton, K, Forero-Torres, A, Liu, R, Jolin, H, Gautam, A & Gallamini, A 2021, 'Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study', Haematologica. https://doi.org/10.3324/haematol.2021.278438

TY - JOUR

T1 - Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma

T2 - a detailed analysis from the phase III ECHELON-1 study

AU - Evens, Andrew M

AU - Connors, Joseph M

AU - Younes, Anas

AU - Ansell, Stephen M

AU - Kim, Won Seog

AU - Radford, John

AU - Feldman, Tatyana

AU - Tuscano, Joseph

AU - Savage, Kerry J

AU - Oki, Yasuhiro

AU - Grigg, Andrew

AU - Pocock, Christopher

AU - Dlugosz-Danecka, Monika

AU - Fenton, Keenan

AU - Forero-Torres, Andres

AU - Liu, Rachael

AU - Jolin, Hina

AU - Gautam, Ashish

AU - Gallamini, Andrea

PY - 2021/6/24

Y1 - 2021/6/24

N2 - Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.

AB - Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.

U2 - 10.3324/haematol.2021.278438

DO - 10.3324/haematol.2021.278438

M3 - Article

C2 - 34162178

SN - 0390-6078

JO - Haematologica

JF - Haematologica

ER -

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this